Publications
Filters: First Letter Of Last Name is K [Clear All Filters]
“Vector bionomics and malaria transmission along the Thailand-Myanmar border: a baseline entomological survey”, J Vector Ecol, vol. 42, no. 1, pp. 84-93, 2017.
, “A survey of the Th2R and Th3R allelic variants in the circumsporozoite protein gene of P. falciparum parasites from western Thailand”, Southeast Asian J Trop Med Public Health, vol. 35, no. 2, pp. 281-7, 2004.
, “Are Extensive T Cell Epitope Polymorphisms in the Plasmodium falciparum Circumsporozoite Antigen, a Leading Sporozoite Vaccine Candidate, Selected by Immune Pressure?”, J Immunol, vol. 175, no. 6, pp. 3935-9, 2005.
, “Comparison of capillary whole blood, venous whole blood, and plasma concentrations of mefloquine, halofantrine, and desbutyl-halofantrine measured by high-performance liquid chromatography”, American Journal of Tropical Medicine and Hygiene, vol. 51, no. 6, pp. 778-84, 1994.
, “High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria”, Journal of Infectious Diseases, vol. 166, no. 6, pp. 1393-400, 1992.
, “Absorption of intramuscular phenobarbitone in children with severe falciparum malaria”, European Journal of Clinical Pharmacology, vol. 42, no. 1. pp. 107-10, 1992.
, “Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients”, Bulletin of the World Health Organization, vol. 73, no. 5, pp. 631-42, 1995.
, “Mefloquine prophylaxis”, Lancet, vol. 342, p. 551, 1993.
, “Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 89, no. 6, pp. 660-4, 1995.
, “Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria”, Lancet, vol. 341, pp. 1044-9, 1993.
, “KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment and prevention of disease transmission”, Antimicrob Agents Chemother, 2014.
, “Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 88, no. 1. pp. 67-73, 1994.
, “Genetic Diversity in New Members of the Reticulocyte Binding Protein Family in Thai Plasmodium vivax Isolates”, PLoS ONE, vol. 7, no. 3, p. e32105, 2012.
, “Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates”, Exp Parasitol, vol. 114, no. 1, pp. 34-9, 2006.
, “Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi”, Blood, vol. 130, no. 11, pp. 1357-1363, 2017.
, “Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation”, Br J Clin Pharmacol, vol. 80, no. 4, pp. 642-53, 2015.
, “Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border”, Antimicrob Agents Chemother, vol. 59, no. 10, pp. 6375-84, 2015.
, “Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda”, CPT Pharmacometrics Syst Pharmacol, vol. 2, p. e83, 2013.
, “Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda”, J Antimicrob Chemother, vol. 69, no. 11, pp. 3033-40, 2014.
, “Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis”, PLoS medicine, vol. 15, no. 6, p. e1002579, 2018.
, “Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria”, Journal of Pharmacy and Pharmacology, vol. 64, no. 11, pp. 1603-1613, 2012.
, “Deep clinical and biological phenotyping of the preterm birth and small for gestational age syndromes: The INTERBIO-21st Newborn Case-Control Study protocol [version 2; referees: 1 approved]”, Gates Open Research, vol. 2, no. 49, p. 49, 2019.
, “Deep clinical and biological phenotyping of the preterm birth and small for gestational age syndromes: The INTERBIO-21 (st) Newborn Case-Control Study protocol”, Gates Open Res, vol. 2, p. 49, 2018.
, “Deep clinical and biological phenotyping of the preterm birth and small for gestational age syndromes: The INTERBIO-21 (st) Newborn Case-Control Study protocol”, Gates Open Res, vol. 2, p. 49, 2018.
, “Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial”, PLOS CLIN TRIALS, vol. 2, no. 5, p. e20, 2007.
, “Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression”, Eur J Haematol, vol. 100, no. 3, pp. 294-303, 2018.
, “Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression”, Eur J Haematol, 2017.
, “Challenges in tackling tuberculosis on the Thai-Myanmar border: findings from a qualitative study with health professionals”, BMC Health Serv Res, vol. 15, no. 1, p. 464, 2015.
, “Immunization Coverage in Migrant School Children Along the Thailand-Myanmar Border”, J Immigr Minor Health, 2015.
, “Community engagement for the rapid elimination of malaria: the case of Kayin State, Myanmar”, Wellcome Open Res, vol. 2, p. 59, 2017.
, “The acceptability of mass administrations of anti-malarial drug as part of targeted malaria elimination in villages along the Thai-Myanmar border”, Malar J, vol. 15, no. 1, p. 494, 2016.
, “The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum”, Antimicrob Agents Chemother, vol. 55, no. 3, pp. 1300-4, 2011.
,